Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018
Emi Takashita, Rod S. Daniels, Seiichiro Fujisaki, Vicki L. Gregory, Larisa V. Gubareva, Weiijuan Huang, Aeron C. Hurt, Angie Lackenby, Ha Nguyen, Dmitriy Pereyaslov, Merryn Roe, Magdi Samaan, Kanta Subbarao, Herman Tse, Dayan Wang, Hui‐Ling Yen, Wenqing Zhang, Adam Meijer
Abstract
values were determined. The PA variant viruses showed 6-17-fold reduced susceptibility to baloxavir. Overall, in the 2017-18 period the frequency of circulating influenza viruses with reduced susceptibility to NAIs or baloxavir was low, but continued monitoring is important.
Topics & Concepts
ZanamivirVirologyNeuraminidaseOseltamivirNeuraminidase inhibitorVirusInfluenza A virusBiologyMedicineCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)DiseasePathologyInfluenza Virus Research StudiesRespiratory viral infections researchViral Infections and Immunology Research